Company Information

CIN
Status
Date of Incorporation
18 March 2003
State / ROC
Delhi / ROC Delhi
Last Balance Sheet
31 March 2023
Last Annual Meeting
29 August 2023
Paid Up Capital
480,427,326
Authorised Capital
500,000,000

Directors

Maximilian Alexander Bohmer
Maximilian Alexander Bohmer
Director/Designated Partner
about 2 years ago
Marc Alexander Mahl
Marc Alexander Mahl
Director/Designated Partner
about 2 years ago
Sylwia Malinowska
Sylwia Malinowska
Director/Designated Partner
over 2 years ago
Nikhil Kulshreshtha
Nikhil Kulshreshtha
Director/Designated Partner
over 3 years ago
Uday Chandrashekhar Shetty
Uday Chandrashekhar Shetty
Director/Designated Partner
over 4 years ago
Arvind Kumar Sharma
Arvind Kumar Sharma
Director/Designated Partner
over 7 years ago
Rakesh Bhargava
Rakesh Bhargava
Director
over 16 years ago
Anand Chand Burman
Anand Chand Burman
Director
over 16 years ago
Mohit Burman
Mohit Burman
Director
over 17 years ago
Chandrakant Birla
Chandrakant Birla
Director
almost 20 years ago
Naresh Trehan
Naresh Trehan
Director
over 21 years ago
Ajay Kumar Vij
Ajay Kumar Vij
Director
over 22 years ago
Amit Burman
Amit Burman
Director
over 22 years ago
Pritam Das Narang
Pritam Das Narang
Director
over 22 years ago

Past Directors

Maurizio Villa
Maurizio Villa
Additional Director
over 3 years ago
Sandeep Kumar Chotia
Sandeep Kumar Chotia
Cfo(kmp)
almost 8 years ago
Karsten Peter Lerch
Karsten Peter Lerch
Additional Director
almost 9 years ago
Steffen Georg Roser
Steffen Georg Roser
Director
over 9 years ago
Maria Gobbi
Maria Gobbi
Managing Director
over 10 years ago
Rajiv Lochan Jain
Rajiv Lochan Jain
Director
over 11 years ago
Satish Bapusaheb Kulkarni
Satish Bapusaheb Kulkarni
Alternate Director
almost 13 years ago
Dheeraj Chopra
Dheeraj Chopra
Person Incharge
about 14 years ago
Dilip Girdharlal Shah
Dilip Girdharlal Shah
Director
over 16 years ago
Michael Schonhofen
Michael Schonhofen
Additional Director
over 17 years ago
Nitin Ram Potdar
Nitin Ram Potdar
Additional Director
over 17 years ago
Ashok Vij
Ashok Vij
Director
almost 19 years ago
Rama Mukherjee
Rama Mukherjee
Director
over 22 years ago

Patents

Automated Metered Drug Dispensing Means

The present invention relates generally to the field of dispensing system. More particularly, the invention relates to a device for dispensing medicament. It may be used for delivering drugs in liquid form at predetermined rates. The main advantage associated with this invention is that the device is powerhl and ...

Salts Of Pralatrexate.

The present invention relates to polymorphic forms of salt of Pralatrexate, process for the preparation thereof, and pharmaceutical compositions thereof.

"Amorphous Form Of Cabazitaxel And Process For Its Preparation"

The present invention relates to Amorphous Form of 4 - acetoxy - 2a - benzoyloxy -Sß - 20 - epoxy - 1 - hydoxy - 7ß, 10ß - dimethoxy - 9 - oxotan - 11 - en - 13α - yl {2R,3S) -3 - tert - butoxycarbonylamino - 2 - hydoxy - 3 - phenylpropionate, i.e Cabazitaxel, methods for its preparation and pharmaceutical compositi...

Process For Preparing Stable Pharmaceutical Compositions Of Compounds Suscesptible To Hydrolysis

The present invention relates to a process of preparing a stable pharmaceutical composition of compounds which are susceptible to hydrolysis comprising a. Addition of required quantity of pharmaceutically acceptable lyophilization excipients optionally in Water for Injection in a formulation vessel; b. Addition o...

Intermediates Of Temsirolimus And Their Preparation

Novel intermediates, process for their preparation and their use in the preparation of therapeutically effective antineoplastic agents, in particular Temsirolimus of formula (I).

Pharmaceutical Compositions Comprising Afatinib

The present invention relates to a tablet comprising Afatinib or a pharmaceutically acceptable salt thereof wherein the tablet is obtained by direct compression. The present invention further relates to a process for manufacturing a tablet of the invention as well as the use of the tablet of the invention. ...

Pharmaceutical Compositions Of Proteasome Inhibitor

The present invention relates to a stable ready to use pharmaceutical composition comprising the proteasome inhibitor carfilzomib or pharmaceutically acceptable salt thereof.

"An Improved Process For The Preparation Of Alpha Form Of Imatinib Mesylate"

An improved process, which is simple, convenient, economical and industrially viable, for the preparation of stable, free flowing, non-hygroscopic crystalline alpha form of Imatinib mesylate, free from the beta form. The process comprises a) providing a clear solution of imatinib base in organic solvent; b) optional...

Polymorphic Forms Of Afatinib Free Base And Afatinib Dimaleate

Abstract The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline form...

Stable Pharmaceutical Compositions Of Rapamycin Esters

A stable pharmaceutical compositions of Rapamycin Esters, in particular Rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid that is free of antioxidants and a process of preparing the same.

"Pharmaceutical Compositions Of Pemetrexed"

A pharmaceutical composition of Pemetrexed represented by formula I, which is a liquid ready to use solution formulation or a lyophilized pharmaceutical composition for parenteral administration comprising a pharmaceutically acceptable organic amine, an inert gas and optionally containing at least one or more ph...

A Process For The Preparation Of Xylene Linked Cyclam Compounds

The present invention relates to an improved process for the preparation of xylene linked cyclam compounds. More particularly the invention provides a process for preparation of high purity plerixafor which does not involve the use of expensive chemicals, hazardous reagents or tedious purification techniques. Invent...

Improved Process For Preparation Of Pralatrexate

An improved process for the preparation of Pralatrexate which is less hazardous. The invention further relates to novel intermediates and process thereof useful for the preparation of Pralatrexate. The present invention also relates to a substantially pure Pralatrexate and a process for obtaining the same in hi...

Process For The Preparation Of Pyrazole Substituted Aminoheteroaryl Compounds

The present invention relates to an improved process for the Preparation of Pyrazole substituted aminoheteroaryl compounds. More particularly, the present invention provides a highly pure 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine and its Intermediates. ...

"An Improved Process For The Preparation Of Bendamustine Hydrochloride"

The present invention relates to an improved process for the synthesis of bendamustine, in particular , bendamustine hydrochloride of the formula (VI) and its intermediate l-Methyl-5-[bis(2-chloroethyl)amino]-1H-benzimidazol-2-yl]lithium butanoate of formula(V), both having a purity of >99%, which is simple, conveni...

An Improved Process For The Preparation Of Pemetrexed

An improved process for the preparation of Pemetrexed of Formula I or its salt, the process comprisesReacting 4-(2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]-pyrimidin-5-yl)-ethyl) benzoic acid with L-glutamic acid or its ester, or its acid salt, in the presence of acid activating reagent having carbodiimide group...

Stable Pharmaceutical Composition Of 5 Aza 2'deoxycitidine

The present invention relates to ready to use, non aqueous pharmaceutical compositions comprising 5-aza-2"deoxycitidine and at least one aprotic solvent. The pharmaceutical compositions may further comprise at least one protic solvent. The present invention also relates to processes for preparating the pharmaceut...

"An Improved Process For The Preparation Of Cabazitaxel"

The present invention relates to an improved process for the preparation of Cabazitaxel and its Intermediates, which avoids the use of hazardous reagents, like Pyridine for silylation and 3HF.Et3N for deprotection of silyl group.

Pharmaceutical Compositions Of Geeitinib

The present invention provides a pharmaceutical composition comprising 4-(3"-chloro-4"-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy) quinazoline (Gefitinib) or a pharmaceutically acceptable salt thereof and a film coating comprising a vinyl polymer.

Pharmaceutical Compostions Of Borotezomib

The present invention relates to stable parenteral pharmaceutical compositions comprising Bortezomib or its pharmaceutically acceptable salts or solvates thereof and stabilizing agent selected from water soluble polymer and amino acids. Said compositions further comprise suitable co-solvents and optionally pharma...

"Novel Intermediates And Process For The Preparation Of Lapatinib And Its Pharmaceutically Acceptable Salts"

The present invention relates to novel intermediates and its use in the preparation of Lapatinib and its pharmaceutically acceptable salts thereof. The present invention also relates to a novel process for the synthesis of Lapatinib and its pharmaceutically acceptable salts thereof. In particular, the present invent...

"A Process For Preparing Crystalline Cabazitaxel Form 1"

The present invention relates to the Crystalline Forms of 4-acetoxy-2a-benzoyloxy-5ß-20-epoxy-1 -hydoxy-7ß, 10ß-dimethoxy-9-oxotan-11 -en-13α-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydoxy-3-phenylpropiona'te, i.e Cabazitaxel, methods for its preparation and Pharmaceutical composition thereof.

"Stable Ready To Use Pharmaceutical Composition Of Pemetrexed"

The present invention relates to a stable ready to use pharmaceutical composition comprising the known compound Pemetrexed that is free of any antioxidants or amino acids or chelating agents; which liquid composition is stable and pharmaceutically elegant.

A Process For Purification Of Carfilzomib

ABSTRACT The present invention relates to a process for the purification of Carfilzomib of Formula I that reduces the level of an acetamide impurity of Formula II preferably below 0.10 wt%.

"An Improved Process For The Preparation Of Melphalan And Its Salts"

The present invention discloses a process for preparing a highly pure Meiphalan of Formula (I) or its pharmaceutically acceptable salt. comprising the steps of; a) reductively alkylating a compound of Formula (II), wherein R is C1-C6 Alkyl and P is a suitable protecting group in the presence of a triflate and a b...

An Improved Process For The Preparation Of Boronic Acid Esters

The present invention relates to an improved process for the preparation of a compound of formula I, Formula I wherein PG1 may be independently selected from tert-butyloxycarbonyl (Boc), phthaloyl, 9-fluorenylmethyloxycarbonyl (Fmoc), triphenylmethyl (Trityl), carboxybenzyl (Cbz), trifluoroacetyl, benzyl (Bn), ben...

An Improved Process For The Preparation Of Ribociclib And Its Salts

ABSTRACT The present invention relates to a process for the preparation of ribociclib or its salts. The invention also provides novel crystalline forms of ribociclib succinate and ribociclib trifluoroacetate.

A Process For Purification Of Carfilzomib Intermediate

The present invention relates to a process for the purification of compound of formula II, Formula II wherein X may be independently selected from trifluoroacetic acid, hydrochloric acid, hydrobromic acid, p-toluene sulfonic acid or phosphoric acid; its isolation as solid and use for the preparation of carfilz...

Polymorphic Forms Of Belinostat And Processes For Preparation Thereof

The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of said polymorphic forms of Belinostat and use thereof in the treatment of a patien...

A Process For The Preparation Of Treosulfan

The present invention relates to a process for the preparation of Treosulfan using sodium borohydride and iodine as reducing agent, which is less hazardous and convenient as compared to the reagents used in the prior art. The invention also relates to a novel intermediate to obtain Treosulfan in high yield and high ...

Stable Liquid Composition Of Pemetrexed

The present invention relates to a stable liquid pharmaceutical composition of pemetrexed for parenteral administration. The invention provides composition comprising pemetrexed diacid, an organic amine and cyclodextrin. The composition may further comprise an inert gas. The composition can be ready to use infusion...

An Improved Process For The Preparation Of Ixazomib Citrate

The present invention relates to an improved process for the preparation of compound of formula I, Particularly, it relates to preparation of compound of formula Ia,from compound of formula Ila and Ilia wherein, X is imidazole or triazole The present invention also relates to preparation of an amorphous form of ...

A Process For Preparing Alectinib Or A Pharmaceutically Acceptable Salt Thereof

The present invention relates to a process for preparing the Alectinib or a pharmaceutically acceptable salt thereof. The invention also relates to novel polymorphic forms of Alectinib and Alectinib hydrochloride.

An Improved Process For The Preparation Of Venetoclax

The present invention relates to a process for the preparation of a compound of formula I or its salts, Formula I wherein R is C1-4 alkyl; and its use for the preparation of the compound of formula V, Formula V

Process For The Preparation Of Acalabrutinib And Its Intermediates

The present invention provides an improved and industrially viable process for the preparation of Acalabrutinib and its intermediates in high yield and eliminating the use of time-consuming purification process. The present invention also relates to the purification of (S)-4-(8-Amino-3-(pyrrolidin-2-yl)imidazo[1,5-a...

An Improved Process For The Preparation Of Semaglutide Side Chain

The present invention relates to an improved process for the preparation of a compound of Formula 1, O O O NH O O O NH O O O NH O O O HN O OH HN O O 10 Formula 1 The invention also provides improved processes for the preparation of intermediates used in the synthesis of Formula 1. The compound ...

Pharmaceutical Compositions Of Pemetrexed

A pharmaceutical composition of Pemetrexed represented by formula I, which is a ready to use solution composition or a or a lyophilized pharmaceutical composition for parenteral administration comprising pharmaceutically acceptable organic amine or their mixtures thereof, an inert gas and optionally containing at ...

Process For The Preparation Of Propofol

Process for the preparation of propofol The present provides a simple, convenient and time-efficient process for the preparation of propofol. Particularly, the present invention provides an improved process for the preparation of propofol using a heterocyclic base for the decarboxylation reaction. ...

An Improved Process For The Preparation Of Remimazolam

ABSTRACT The present invention relates to an improved process for the preparation of a compound of formula V or a salt thereof, Formula V The present invention also provides a process for the preparation of a compound of formula I, used in the synthesis of the compound of formula V, Formula I w...

Process For The Preparation Of Tetrapeptide Fragment Of Liraglutide

The present invention relates to an improved process for the preparation of a a tetrapeptide of formula I, Formula I wherein R1 and R2 are independently selected from an amine protecting group and R3 is t-Bu or Bn. The present invention further, relates to a process for the preparation Liraglutide or its...

A Process For The Preparation Of Cdk Inhibiting Pyrrolopyrimidine Compounds

ABSTRACT The present invention relates to an improved process for the preparation of CDK inhibiting pyrrolopyrimidine compounds. More particularly the invention provides a process for preparation of high purity 2'-{[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino}-7',8'¬ dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',...

Registered Trademarks

Fresubin Dm Fresenius Kabi Ag

[Class : 5] Pharmaceutical, Medicinal And Ayurvedic Preparations And Substances, Dietetic Food And Substances Adapted For Medical Use, Dietary Supplements For Humans, Nutritional Supplements, Nutraceutical Preparations For Therapeutic Or Medical Purposes, Nutraceuticals For Use As Dietary Supplements

Fresubin Lp Fresenius Kabi Ag

[Class : 5] Pharmaceutical, Medicinal And Ayurvedic Preparations And Substances, Dietetic Food And Substances Adapted For Medical Use, Dietary Supplements For Humans, Nutritional Supplements, Nutraceutical Preparations For Therapeutic Or Medical Purposes, Nutraceuticals For Use As Dietary Supplements

Fresubin Hepa Fresenius Kabi Ag

[Class : 5] Pharmaceutical, Medicinal And Ayurvedic Preparations And Substances, Dietetic Food And Substances Adapted For Medical Use, Dietary Supplements For Humans, Nutritional Supplements, Nutraceutical Preparations For Therapeutic Or Medical Purposes, Nutraceuticals For Use As Dietary Supplements
View +126 more Brands for Fresenius Kabi Oncology Limited.

Charges

0
29 September 2008
Idbi Bank Limited
19 Crore
16 July 2008
Punjab National Bank
15 Crore
31 December 2003
Idbi Bank Limited (lead Bank)
139 Crore
29 September 2006
Hsbc Bank Plc
67 Crore
29 September 2008
Idbi Bank Limited
0
29 September 2006
Hsbc Bank Plc
0
31 December 2003
Idbi Bank Limited (lead Bank)
0
16 July 2008
Punjab National Bank
0
29 September 2008
Idbi Bank Limited
0
29 September 2006
Hsbc Bank Plc
0
31 December 2003
Idbi Bank Limited (lead Bank)
0
16 July 2008
Punjab National Bank
0